1/8/2024 0 Comments Bc studio san antonioGS2-02: Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated survival results of the randomized, phase 3 study DESTINY-Breast03 Krop I, Park YH, Kim S-B, Borges G, Aksoy S, Gregori JG, Roylance R, Lim E, Yerushalmi R, Zagouri F, Duhoux FP, Fehm T, Takano T, Egorov A, Wu I, Cathcard J, Chu C, Andre F. Yale Cancer Center, New Haven, CT, USA Samsung Medical Center, Seoul, Republic of Korea Asan Medical Center, Seoul, Republic of Korea Clínica de Neoplasias Litoral, Santa Catarina, Brazil Hacettepe University Medical Faculty, Ankara, Turkey Instituto Valenciano de Oncologia, Valencia, Spain University College London Hospital, London, UK St Vincent’s Hospital Sydney, Sydney, NSW, Australia Rabin Medical Center-Beilinson Campus, Petah Tikva, Israel General Hospital of Athens Alexandra, Athens, Greece Cliniques Universitaires Saint-Luc, Bruxelles, Belgium Universitaetsklinikum Düsseldorf AöR, Düsseldorf, Germany The Cancer Institute Hospital of JFCR, Tokyo, Japan Daiichi Sankyo, Basking Ridge, NJ, USA Institut Gustave Roussy, Villejuif, France GS2-01: Trastuzumab deruxtecan vs physician’s choice in patients with HER2+ unresectable and/or metastatic breast cancer previously treated with trastuzumab emtansine: primary results of the randomized phase 3 study DESTINY-Breast02 Leveraging Preclinical Models for Translational Breast Cancer Research Opening Ceremony/Welcome Message - Hall 3 Special Populations: Male Breast Cancer/Geriatrics SPOTLIGHT POSTER DISCUSSION SESSION #6 - Stars at Night Ballroom 1&2 SPOTLIGHT POSTER DISCUSSION SESSION #5 - Stars at Night Ballroom 3&4 Spatial Imaging and the Importance of Localization Laboratory for Translation Breast Cancer Research/KU Single Cell Genomics for Breast Cancer Outcomes Single Cell Approaches for Translational Research and Biomarker Discovery SPOTLIGHT POSTER DISCUSSION SESSION #4 - Hemisfair Ballroom 1&2
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |